ARTV
Artiva Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.19
+0.58%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | 251.0K | 33.5M | 4.9M |
| Cost of Revenue | 666.0K | 2.6M | — | — | — |
| Gross Profit | (666.0K) | (2.6M) | 251.0K | 33.5M | 4.9M |
| Operating Expenses | |||||
| R&D Expense | 75.9M | 69.5M | 50.3M | 50.3M | 44.0M |
| SG&A Expense | 20.3M | 20.3M | 17.2M | 13.9M | 20.8M |
| General & Admin Expense | 20.3M | 20.3M | 17.2M | 13.9M | 20.8M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (666.0K) | (1.8M) | — | — | — |
| Total Operating Expenses | 95.5M | 88.0M | 67.5M | 64.2M | 64.8M |
| Cost and Expenses | 96.1M | 90.6M | 67.5M | 64.2M | 64.8M |
| Operating Income (EBIT) | (96.1M) | (90.6M) | (67.3M) | (30.7M) | (59.8M) |
| Non-Operating | |||||
| Interest Income | 5.3M | 6.0M | 5.3M | 2.5M | 1.3M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 5.3M | 6.0M | 5.3M | 2.5M | 1.3M |
| Other Non-Op Income/Expense | 5.3M | 6.7M | 8.8M | 3.0M | 1.5M |
| Non-Operating Income (excl Interest) | (5.3M) | (6.7M) | (8.8M) | (3.0M) | (1.5M) |
| EBT (Pre-Tax Income) | (90.8M) | (83.9M) | (58.5M) | (27.6M) | (58.3M) |
| Income Tax Expense | — | — | — | 72.0K | 53.0K |
| Bottom Line | |||||
| Net Income | (90.8M) | (83.9M) | (58.5M) | (27.7M) | (58.4M) |
| Earnings from Cont. Ops | (90.8M) | (83.9M) | (58.5M) | (27.7M) | (58.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (90.8M) | (83.9M) | (58.5M) | (27.7M) | (58.4M) |
| Per Share | |||||
| Basic EPS | ($3.31) | ($3.43) | ($5.20) | ($1.19) | ($3.32) |
| Diluted EPS | ($3.31) | ($3.43) | ($5.20) | ($1.19) | ($3.32) |
| Revenue Per Share | $0.00 | $0.00 | $0.01 | $1.44 | $0.28 |
| Shares | |||||
| Basic Shares Outstanding | 39.4M | 24.4M | 24.4M | 23.3M | 17.6M |
| Diluted Shares Outstanding | 39.4M | 24.4M | 24.4M | 23.3M | 17.6M |
| Profitability Metrics | |||||
| EBITDA | (87.5M) | (81.3M) | (56.1M) | (25.4M) | (57.2M) |
| D&A | 3.4M | 2.6M | 2.4M | 2.3M | 1.2M |
| EBIT | (90.8M) | (83.9M) | (58.5M) | (27.6M) | (58.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026